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ABSTRACT 
Background: Osteoarthritis (OA) is the most common degenerative joint disease which 
affects the joint structures leading to disability. Studies in the last 20 years have 
documented the increased prevalence of knee pain and symptomatic knee OA. Similarly, 
of temporomandibular joint (TMJ) disorders OA is the most common. Lysyl oxidase like-
2 (LOXL2) is a copper-dependent amine oxidase. previous studies showed that LOXL2 is 
elevated during mouse fracture healing. Our hypothesis that LOXL2 acts as a specific 
anabolic factor in chondrocytes 
Methods: The activity of LOXL2 in human articular and TMJ chondrocytes was 
assessed by cell-based assays and RT-qPCR, and LOXL2-mediated activation of NF-κB 
and extracellular signal-related kinase (ERK) signaling pathways was measured by 
western blotting. To examine LOXL2-induced effect in vivo, we implanted Matrigel-
imbedded human chondrocytes into nude mice and exposed them to exogenous LOXL2 
for 6 weeks. We also examined if LOXL2 induces the proliferation of OA chondrocytes. 
		 vii 
Results: LOXL2 staining was detected in damaged regions of human TMJ, hip and knee 
joints affected by OA. Stimulation with transforming growth factor (TGF)-β1 
upregulated LOXL2 expression, while pro-inflammatory cytokines IL-1β and TNF-α 
downregulated LOXL2, in human chondrocytes. LOXL2 expression also inhibited IL-1β-
induced phospho-NF-κB/p65 and TGF-β1-induced ERK1/2 phosphorylation. Matrigel 
constructs of human chondrocytes from the knee joint and TMJ implanted in nude mice 
showed anabolic responses after LOXL2 transduction, including increased expression of 
SOX9, ACAN, and COL2A1. We have found that LOXL2 does not induce the 
proliferation of human TMJ or knee OA chondrocytes. 
Conclusions: we showed that LOXL2 induces differentiation and attenuates OA related 
catabolic signaling pathways. 
Keywords: LOXL2, Knee, TMJ,  Anabolic response, Cartilage, Osteoarthritis 
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INTRODUCTION & LITERATURE REVIEW 
 
 Osteoarthritis (OA) is the most common form of the degenerative joint disease, 
leads to structural damage and ultimately loss of function and disability. It occurs when the 
cartilage or the cushion between joints break down leading to pain, stiffness, and swelling.  
OA affects an estimated 10% of men and 18% of women over 60 years of age. Progressive, 
irreversible destruction of the joints in OA is driven by defective cartilage extracellular 
matrix (ECM) remodeling and the loss of chondrocytes due to apoptosis (Zamli Z. 2011). 
Knee pain and symptomatic knee OA have increased in prevalence (Nguyen US, 
2011), and similar manifestations of the disease process are seen in temporomandibular 
joint (TMJ) disorders (Scrivani SJ, 2008). Advances in understanding the disease 
pathogenesis are critical to OA prevention and treatment. LOX activity is required for the 
formation of immature and mature pyrodinoline (PYR) cross-links in native and engineered 
cartilage. Hypoxia-induced LOX increases PYR crosslinks and tensile properties of the 
articular cartilage, knee meniscus, patellar tendon, and anterior and posterior cruciate 
ligaments, while exogenously applied LOX proteins are capable of enhancing collagen 
cross-linking and cartilage tissue functional properties (Makris EA, 2014). 
Lysyl oxidase (LOX) and the four lysyl oxidase like proteins, LOXL, LOXL2, 
LOXL3, and LOXL4, are copper-containing amine oxidases constituting a heterogeneous 
family of enzymes that oxidize primary amine substrates to reactive aldehydes, catalyzing 
the cross-linking of extracellular matrix (ECM) proteins (Csiszar, K. 2001). Each of the 
five proteins differs primarily in their N-terminal sequence, which may confer individual 
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functions (Molnar, J et al. 2003). Structural similarities of the highly conserved copper-
binding and lysyl-tyrosylquinone cofactor sites among the LOX and LOXL-2 proteins may 
result in similar amine oxidase activities. The specific novel functions of each are 
determined by other conserved domains, such as the cytokine receptor-like domain (shared 
by all LOXs) and the multiple scavenger receptor cysteine-rich domains (SRCR), that are 
present in LOXL2, LOXL3 and LOXL4 (Csiszar, K. 2001). 
Recent studies reveal that LOX and LOXL proteins influence cell behavior such as 
chemotactic responses, proliferation, and shifts between the normal and malignant 
phenotypes (Lucero, HA et al. 2006), LOX oxidizes the side chain of peptidyl lysine 
converting specific lysine residues to residues of alpha-aminoadipic-delta-semialdehyde. 
This post-translational change results in covalent crosslinking of the component chains of 
fibrillar collagen and those of elastin by allowing for the condensation of the aldehydes 
with neighboring amino groups or other aldehydes. This, in turn, is essential for the 
stabilization of collagen fibrils and the elasticity and integrity of mature elastin (Lucero, 
HA et al. 2006). LOX therefore heavily determines the mechanical properties of the 
extracellular matrix (ECM) and connective tissues. The importance of LOX derived cross-
linking was first established from animal studies in which LOX was inhibited either by 
nutritional copper-deficiency or by supplementation of diets with β-aminopropionitrile 
(BAPN), which is an inhibitor of LOX. This resulted in lathyrism, which is characterized 
by abnormalities correlating with decreased cross-linking of collagen and elastin (Dawson, 
DA et al. 2002). 
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Expression of LOX is regulated by hypoxia-inducible factors and it is therefore 
often upregulated by hypoxic breast and head and neck tumors. The secreted LOX is 
responsible for the invasive properties of hypoxic cancer cells through focal adhesion 
kinase activity and cell-to-matrix adhesion, thereby permitting metastatic cancer (Erler, JT 
et al. 2006). ECM remodeling is a common feature of diverse pathological processes. The 
dysregulation of LOX can be responsible for the onset and progression of multiple 
pathologies affecting the connective tissue, such as fibrotic processes, tumor progression, 
metastasis, and neurodegenerative and cardiovascular diseases. Inhibitors of the LOX 
enzyme may be useful in preventing tumor progression and metastasis as well as treating 
other fibrotic diseases that involve the remodeling of the extracellular matrix (Rodriguez, 
C. et al. 2008). 
Like the other LOX family members, LOXL2 contains a copper-binding motif, 
lysyl-tyrosyl-quinone residues and a cytokine receptor-like domain at its conserved C-
terminus (Kagan, HM et al. 2003). LOXL2 possesses amine oxidase activity in peptidyl 
lysine residues in collagen and elastin, suggesting that LOXL2 has a similar cross-linking 
role to LOX (Csiszar, K. 2001). The presence of the cytokine receptor-like and SRCR 
domains suggest additional roles for LOXL2, including cell motility and adhesion in 
addition to its catalytic function. Upregulation of LOXL2 has been observed in cancers of 
the breast, esophagus, prostate, pancreas, head and neck, and bile ducts. High levels of 
LOXL2 expression have been associated with more aggressive colon, gastric and breast 
cancers (Barker, H. et al. 2012). Expression of the protein has been clinically correlated 
with metastasis and decreased survival of breast cancer patients (Kim, YM et al. 2011). 
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LOXL2 has been shown to play a role in epithelial to mesenchymal transition, primary 
tumor cell invasion, chemoresistance, angiogenesis, and remodeling of the 
microenvironment, suggesting that LOXL2 is a potential therapeutic target for the 
prevention of metastatic disease (Barker, H et al. 2011). 
The importance of LOX ranges in its role of stabilizing the ECM, to its influence 
in cell proliferation, and its effect on osteoblast differentiation in bone formation. Despite 
that the LOX family members have been reported to function as tumor suppressors, recent 
studies have shown that both LOX and LOXL2 promote tumor cell invasion and metastasis 
(Nishioka, T et al. 2012). 
The LOX family plays a critical role in the formation and repair of the extracellular 
matrix (ECM). The ECM is the extracellular part of animal tissue that usually provides 
structural support to cells, segregates tissues from one another, and regulates intercellular 
communication. Formation of the ECM is essential for processes like growth, wound 
healing and fibrosis. The ECM is composed of a complex mixture of proteoglycans and 
proteins, of which include collagen and elastin. The tensile strength and structural integrity 
of collagen in the ECM relies on the role LOX plays in the stabilization of structural 
components. LOX also has an essential central role in the morphogenesis and repair of 
connective tissues of the cardiovascular, respiratory, skeletal, and other systems of the body 
(Kagan, H et al. 2003). Therefore, the dysregulation of LOX could underlie the onset and 
progression of multiple pathologies that affect connective tissue, such as fibrotic processes, 
neurodegenerative and cardiovascular disease, and tumor progression and metastasis. 
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ECM remodeling is a common feature of diverse pathological pathways, including 
not only tissue fibrosis but cancer as well. Because of the critical role the LOX family plays 
in ECM crosslinking and remodeling, they are implicated in cancer progression and 
metastasis. Despite LOX having been shown to be a tumor suppressor, LOX is now more 
widely accepted as a poor prognosis factor, especially in promoting cancer metastasis in 
breast, head and neck squamous cell, lung, prostate, and bronchogenic carcinomas. LOXL2 
is a novel poor prognosis marker of lung squamous cell carcinomas, lung adenocarcinomas 
and pancreatic carcinoma. Inhibition of LOX activity by pharmacological inhibitors, 
therapeutic antibodies or reduced LOX expression, shows to impede tumor progression. 
The LOX family can modulate tumor behavior through ECM remodeling and its 
microenvironment. In solid tumors, there is evidence of the pervasive growth of dense 
fibrous tissues with an accumulation of fibroblasts or an excess of ECM deposition. Cancer 
invasion is facilitated by stromal collagen re-organization and is significantly increased in 
collagen-dense tissues. Many ECM modifying enzymes, including the LOX family, are 
aberrantly expressed during malignant transformation, progression and metastasis of 
cancers. The overexpression of active LOX can increase tissue tension and ECM rigidity 
by crosslinking elastins and collagens. 
This stiff microenvironment allows cancer cells to be more proliferative and to 
invade into the surrounding matrix. It has been shown that reduced collagen crosslinking 
by the downregulation of LOX impedes tumor progression. The inhibition of LOXL2 
results in a reduction of activated fibroblasts, desmoplasia and metastasis (Xiao, Q et al. 
2012). The expression of LOX is also regulated by hypoxia-inducible factors and it is 
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therefore often upregulated by hypoxic breast and head and neck tumors. Hypoxia is a 
characteristic of many malignancies. Hypoxia promotes tumor angiogenesis, epithelial-
mesenchymal transition, invasion, metastasis, and de-differentiation; these are largely 
mediated by the targets of hypoxia-inducible factors.  In hypoxic cancer cells, the hypoxia-
inducible factor-1 (HIF-1) binds to the hypoxia-responsive element in the promoter region 
of target genes, including LOX and LOXL2. It has been shown that hypoxia-induced 
cancer cell invasion is severely impaired by inhibiting LOX expression or oxidase activity 
(Nishioka, T et al. 2012). In one study, knockdown of HIF-1 or hypoxia-induced LOX 
family members reduced collagen cross-linking, CD11b(+) bone marrow-derived cells 
recruitment, and metastasis formation in the lungs of mice after orthotopic transplantation 
of human breast cancer cells (Wong, C et al. 2011). For these reasons, a higher LOX or 
LOXL2 expression is associated with poor prognosis in cancer patients. 
LOX is also essential for the structural integrity and function of bone tissue. The 
extracellular bone matrix is primarily composed of type 1 collagen, which is the major 
determinant for the mechanical properties of bone tissue. Post-translational modifications 
to collagen result in the formation of a mature functional matrix. These modifications are 
also essential for matrix mineralization. As stated before, the extracellular post-
translational modifications of fibrillar collagens by LOX are critical for collagen cross-
linkage and therefore the accumulation of a functional collagen matrix in bone tissue. It 
has been shown that LOX appears to be regulated during osteoblast cell differentiation. 
This regulation is required for normal collagen deposition. Diminished LOX enzyme 
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activity can result in an increased risk of bone deformities and fractures (Pischon, N et al. 
2009). 
The biosynthesis of LOX is a complex, multistep pathway that requires numerous 
post-translational modifications. The processing of prolysyl oxidase to lysyl oxidase first 
begins with lysyl oxidase messenger RNA translation, which produces proLOX, and 
contains 417 amino acids (Grimsby, J et al. 2010).  This proLOX enters into the RER where 
its signal peptide, a 21 amino acid signal sequence, is cleaved. The N-terminal propeptide, 
comprising of 147 amino acid residues, is then glycosylated within the ER at an Asn residue 
located in the propeptide region (Trackman, P et al. 1992). The C-terminal sequence, 
containing the 249 amino acid residue mature protein, is folded while acquiring at least 
three disulfide bonds. The addition of copper, a cofactor of the functional catalyst, and the 
formation of lysine tyrosylquinone cofactor may occur in the ER or during protein 
trafficking through the Golgi body elements. It is then transported into vesicles for its 
secretion into the extracellular space as proLOX, a 50 kDa glycoprotein precursor. At the 
cell surface, the glycosylated N-terminal propeptide of proLOX is then proteolytically 
cleaved between Gly-168 and Asp-169 by procollagen C proteinase, releasing a 
catalytically active mature 32 kDa LOX enzyme (Lucero, et al. 2006). 
The LOXL2 mRNA encodes an 87 kDa polypeptide that shares a 48% identity with 
the LOX polypeptide in its amino acid sequence from residue 546 to 751 in its C-terminal 
region. This region contains all conserved amino acid sequences needed for the proper 
function of the mature 32 kDa form of the LOX enzyme (Saito, H el at. 1997). 
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Previous studies showed that a member of the LOX family, LOXL2, is elevated during 
fracture healing in mice and that it promotes chondrogenesis and the formation of cartilage 
ECM (Ravindra PV, 2009) & (Iftikhar M,2011). Whether LOXL2 plays any role in the 
pathophysiology of OA and the effect on cartilage is not known. 
Pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α and interleukin 
(IL)-1β are catabolic cytokines (Mueller MB, 2011) involved in chondrocyte apoptosis and 
matrix proteolysis; they contribute to the pathophysiology of OA (Cho TJ, 2003) Anti-
cytokine agents have been evaluated for OA therapy, but with limited success (Calich AL, 
2010)& (Ravindra PV, 2009). Anabolic factors that have roles in chondrogenesis and 
articular cartilage maintenance have been used as additive factors in tissue engineering 
strategies and are considered as candidate structure-modifying agents for OA therapy 
(Goldring MB,2015).  Examples are fibroblast growth factor-18 (Lohmander LS, 2014). 
moreover, members of the bone morphogenetic protein 2 (BMP)/ transforming growth 
factor β1 (TGF-β) family. Differential chondrocyte responses due to aging and OA may 
account for off-target effects in joints treated with pro-anabolic agents; such effects can 
result in cartilage calcification, osteophyte formation, angiogenesis, and synovial fibrosis 
(Blaney Davidson EN, 2006) & (van Beuningen HM, 2014).  Thus, alternative approaches 
to regulating these inflammatory cytokines could lead to improved therapies. Our 
hypothesis that LOXL2 acts as a specific anabolic factor in chondrocytes. 
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MATERIAL & METHODS 
 
Human tissues and animal experiments 
Human tissues were obtained with Institutional Review Board (IRB) approval and 
informed consent from all subjects. TMJ tissues were obtained from Boston University 
(IRB H33300). TMJ tissues were selected by clinical features such as TMJ pain and 
mobility and confirmed by pathological diagnostic findings as healthy or TMJ-OA, at the 
Department of Pathology, Boston University. The exclusion criteria included a history of 
any rheumatic disease or cancer. Histological slides from 16 patients (8/condition) 
including TMJ normal (Osteoarthritis Research Society International (OARSI) grade I) and 
TMJ-OA (OARSI grade V) from the right and left joints were obtained. Freshly isolated 
cells from TMJ-OA cartilage from five patients were used for animal experiments. 
Histological slides of tissues from hip joints were obtained from the Department of 
Orthopaedic Surgery, School of Medicine, Boston University, Boston, MA, USA (IRB H-
32517). Tissue sections included both uninvolved and involved regions of the femoral head 
based on micro-computed tomography (microCT) mapping of the regions of cartilage 
erosion relative to bone cysts. 
Histological sample slides were obtained from six individuals. The OA cartilage 
histological tissue slides from the knee joints were obtained from Georgia Medical College, 
Augusta, GA, USA under IRB approval (657441-5). Tibial epiphyses from OA-affected 
regions (OARSI grade V) and the adjacent healthy region (OARSI grade I) were collected 
from five patients. All mouse experiments were performed with guidance and regulations 
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through Boston University Institutional Animal Care and Use Committee (IACUC), 
approval number AN-15387. 
 
Preparation of lentivirus and adenovirus 
Adenoviruses for transient expression of LOXL2 (Ad- CMV-RFP-CMV-hLOXL2-
His; referred to as Ad-RFPLOXL2), and its empty vector (EV) control (Ad-RFP-EV) were 
custom-synthesized (ADV-214438) by Vector Biolabs. These adenovirus particles were 
amplified in 293 T cells and quantified using an adenovirus quantification kit (Cell 
Biolabs). The lentivirus packaging was performed using the 3-plasmid protocol (Bais M, 
2009).  Lentiviral vector for LOXL2 (CMV-LOXL2) and CMV-EV)) were purchased from 
Genecopoeia Inc. (EX-Y2020-Lv128 and LV128;). The expression of LOXL2 protein was 
evaluated by western blotting of the medium and cell layer, and enzymatic activity of 
purified LOXL2 was evaluated by the Amplex Red assay (Palamakumbura AH, 2002). 
 
Human cell cultures 
Human articular chondrocytes (HAC) from three OA patients (HAC-OA) (Cell 
Application Inc. from lot no. 2356, 1777, and 2881) were used. Normal HAC (HAC-N) 
cells were from Lonza (CC-2550). Cell lines were grown in chondrocyte growth medium 
(CGM™ BulletKit™, CC-3216, Lonza Inc.) or in chondrocyte differentiation medium 
(CDM BulletKit, CC-3225, Lonza), both of which contain 5% fetal bovine serum (FBS), 
R3-insulin-like growth factor-1, human recombinant fibroblast growth factor-beta; insulin-
transferrin-selenium (ITS), and gentamycin/ amphotericin-B for in vitro studies. The 
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chondrocyte differentiation medium also contains TGF-β3. These supplements have been 
optimized for HAC (van der Kraan PM,2002) & (Pei M, 2008). The medium, with a similar 
composition, from Lonza and Cell Applications optimized for HAC (HAC-O and HAC) 
has been used in several in vitro and in vivo studies ( Dua R, 2016)& (Samavedi S, 2017) 
and in our experiments. Primary TMJ cells were obtained as outgrowths from explants of 
TMJ condylar cartilage within 24 h after collection as 1-mm to 3-mm punch biopsies, and 
cultured in chondrocyte growth medium with 5% FBS (Lonza Inc.). 
 
Immunofluorescence of human tissue sections 
Human tissues were fixed in 4% paraformaldehyde overnight, paraffin-embedded, 
and sectioned for subsequent immunofluorescence by standard procedures. The tissue 
sections were exposed to anti-LOXL2-specific antibodies (GeneTex) or isotype control 
antibody; primary antibodies were detected with anti-biotin antibody combined with 
streptavidin-conjugated Texas red Sections were viewed under epifluorescence 
microscopy (Zeiss 710). Quantification of images was performed using Image J software 
(NIH), as shown in an earlier study (McCloy RA, 2014). Briefly, the region of interest was 
selected by drawing the margins. Parameters were set to measure area, integrated density, 
and mean fluorescence for stained regions, and data were obtained from several regions. 
Next, the same measurements were obtained from adjacent regions as a background 
control. We calculated the total corrected cellular fluorescence (TCCF): 
  TCCF =  Integrated density _  (Area of selected cell x Mean fluorescence of background 
readings).  Data are reported as the fold-change expression compared to control. 
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Cell proliferation assay 
CyQUANT Cell Proliferation Assays kit (Cat. No.C7026; Life Technologies) was 
used to provide an accurate measurement of cell numbers based on DNA content. HAC or 
HAC-OA cells from TMJ or Knee confluence was checked under a microscope and once 
cells reached 80-90% confluence, they were washed with 2 mL of Dulbecco’s phosphate-
buffered saline, and trypsinized with 2 mL 0.25% Trypsin with EDTA (Cat. No. 25200056; 
Gibco) and placed into the humidified incubator for 5 minutes. Five mL of the respective 
medium was added to the trypsinized plate, pipetted up and down and plated 5000/10000 
cells in 24-well plate overnight. The next day cells were treated with recombinant human 
lysyl oxidase homolog 2 protein (Cat. No. 2639-AO; R&D Systems Inc) that was diluted 
to 10 ng/µL in sterilized distilled water, Adv-RFP-EV or Adv-RFP-LOXL2. The next day, 
cells were washed extensively with PBS at least 1 time. After that cells were Trypsinized 
with 0.5 mls of Trypsin EDTA (.25%) for 15-20 min. used cell scraper to scrape the cells 
and then transfer cells to 1.5 ml tube. Tubes were centrifuged for 14,000 rpm for 10 
minutes. The supernatant was removed. Cell pellet were stored at -800C for 15-30 minutes 
to lyse the cells. The concentrated cell-lysis buffer stock solution (Component B) was 
diluted 20-fold in distilled water. The CyQUANT® GR stock solution (Component A) was 
diluted 400-fold into the 1X cell-lysis buffer. 200 ul of the above mixed lysis buffer was 
added to each well and keep at -800C for 15 minute. The plates were placed in the shaker 
and were shaken for 1 hour. 150 ul was transferred of the above solution to new 96 well 
black plate. The control blank solution was added. CyQuant Costar program was chosen in 
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Microwin 2000 program plate reader. The sample fluorescence was measured using a 
fluorescence microplate reader with filters F450 nm excitation and F535 nm emission. The 
reading was taken with lamp energy 7000 and then 15000. Berthold Tech TriStar, Driver 
Version: 1.04, (1.0.4.0), S/N: 25-1070, Embedded Version: 1.04. 
 
Nano-Orange Protein Quantitation 
The purpose of this procedure was to accurately detect protein in solution. The 
NanoOrange® Protein Quantitation Kit (Cat. No. N6666; Invitrogen) included 
NanoOrange® protein quantitation reagent (Component A), BSA Standard (Component 
B), and NanoOrange® protein quantitation diluent. The 1x protein quantitation diluent was 
prepared by mixing the concentrated NanoOrange® protein quantitation diluent and 
diluting it 10-fold in distilled water. The 1x NanoOrange reagent working solution was 
prepared by diluting Component A 500-fold into the 1x protein quantitation diluent. A 10 
µg/mL BSA solution was prepared by diluting the 2 mg/mL Component B 1:200 into the 
1x NanoOrange® working solution. The 10 µg/mL BSA solution was diluted to make 0, 
0.5, 1, 2, 3, and 4 µg/250µL standards. Following the standards, 30 µL of working solution 
was mixed with 10 µL of stock sample making a 2:8 dilution. The diluted tubes were 
centrifuged at 1000 rpm for 3 minutes. 10 µL of the 2:8 diluted sample was then added to 
490 µL of working solution and centrifuged, along with the standards, at 1000 rpm for 2 
minutes. All samples and standards were placed in a 95° C water bath for 10 minutes and 
then cooled for 20 minutes at room temperature. In a 96-well black plate, 200 µL of each 
sample and standards were duplicated and were pipetted into each well and fluorescence 
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was measured. Alongside the samples, DMEM serum-free medium was also duplicated 
and run as a blank for the experiment. Data were analyzed in an Excel spreadsheet by 
calculating the averages of the duplicated (for both the samples and standards), the standard 
deviation and the relative standard deviation. The averaged fluorescence value of the 
reagent blank (0 µg/µL) was subtracted from the average fluorescence value of each 
standard. The corrected values were then used to generate a standard curve of fluorescence 
versus protein concentration. Based on the equation obtained from the standard curve, the 
concentration of protein (µg/µL) was calculated for each sample. 
 
Molecular signaling analysis 
HAC-OA, transduced with either Ad-RFP-LOXL2 or Ad- RFP-EV at MOI 25, 
were incubated in serum-free growth medium for at least 16 h and then left untreated 
(vehicle) or treated for 10 min with 10 ng/mL of IL-1β or TGF-β1. Proteins were extracted 
for western blot analysis. 
 
Western Blot  
The purpose of this procedure was to separate proteins by their molecular weight 
and identify specific proteins with antibody staining procedures. 10% SDS-PAGE gels 
were loaded with equal amounts of protein according to the NanoOrange® quantitation, as 
well as 5 µL of dye and enough sample buffer to equalize all the volumes to 50 µL to load. 
Two protein standards were loaded, 10 µL of Kaleidoscope and 10 µL of SDS-PAGE 
Broadrange. The gel ran for 90-120 minutes at 70 V. Membranes were activated in order 
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to open the pores to facilitate protein binding by placing in methanol for 15 seconds, 
distilled water for 2 minutes, and blotting buffer (made by the lab) for 5 minutes. The gel 
was removed from the electrophoresis chamber and placed between the membrane and 
blotting papers and sponge for transfer. The blot ran overnight in blotting buffer at 66 mA. 
The next day, the membrane was washed with TBS-T (made by the lab) 3 times for 5 
minutes. The membrane was then blocked with 5% nonfat dry milk in TBS-T (1 g per 20 
mL, made by the lab) for 2 hours on a horizontal shaker at room temperature. The gel was 
incubated with primary antibody in the blocking buffer overnight at 4°C on a horizontal 
shaker with gentle agitation. The primary antibody used for the samples Phospho-p44/42 
MAPK (Erk1/2) (Cat. No. #4370; Cell Signaling), p44/42 MAPK (Erk1/2) Antibody (Cat. 
No. #9102; Cell Signaling), Phospho-NF-κB p65 (Ser536) (93H1) Rabbit mAb (Cat. No. 
#3033; Cell Signaling), NF-κB p65 (D14E12) XP® Rabbit mAb (Cat. No. #8242; Cell 
Signaling), β-Actin (13E5) Rabbit mAb (Cat. No. #4970; Cell Signaling), were diluted at 
1:1000 and used. The next day, the membranes were washed for 5 minutes with TBS-T 3 
times on a horizontal shaker. The membranes then were incubated with anti-Rabbit IgG 
HRP-linked secondary antibody (Cat. No. 7074S; Cell Signaling). This secondary antibody 
incubation was done in 5% BSA prepared with TBS-T for 2 hours at room temperature on 
a horizontal shaker with gentle agitation. The membranes were then rinsed with TBS-T 3 
times for 5 minutes per rinsing, and bands were visualized with HyGLO™ Quick Spray 
Chemiluminescent HRP Antibody Detection Reagent (Cat. No. E2400; Denville Scientific, 
Inc.). Membranes were developed using G: BOX machine by syngene, GeneSys Software 
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V1.5.4.0. Quantification was performed using a digital densitometry system (Versadoc; 
BioRad, Hercules, CA, USA) and Image J software. 
 
Alcian Blue Stain pH 1.0  
The purpose of this procedure was to identify sulfated mucosubstances using 
ALCIAN BLUE pH 1.0 STAIN kit procedure (Cat. No. KTABP1; American MasterTech). 
Paraffin-embedded tissue slides were deparaffinized using Xylene changed twice for 5 
minutes and hydrated through absolute alcohol three changes for 1 min then were rinsed in 
running tap water for 1 min. Slides were immersed in 3% Acetic Acid for 3 
minutes.Without rinsing, slides were immersed in Alcian Blue Stain pH 1.0 for 30 
minutes.Next slides were rinsed for 1 minute in running Tap water and then slides were 
Placed in Nuclear Fast Red Stain for 5 minutes. After that slides were rinsed in running 
Tap water for 1 minute and then dehydrated through 3 changes of Absolute Alcohol for 1 
min. Cleared slides through 3 changes of Xylene .Coverslips were used with a permanent 
mounting media. 
 
Safranin O Stain 
Safranin O is specific for acidic proteoglycan present in cartilage tissue sections. 
Safranin O kit procedure (Cat. No. KTSFO; American MasterTech). Paraffin-embedded 
tissue slides were deparaffinized using Xylene changed twice for 5 minutes and hydrated 
through absolute alcohol three changes for 1 min then were rinsed in running tap water for 
1 min. slides were immersed in Weigert’s Haematoxylin for 5 minutes . Next slides were 
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rinsed for 1 minute in running Tap water and then slides were placed in 0.2% Fast Green 
for 5 minutes. Without rinsing, slides were immersed in 1% Acetic acid for 10-15 seconds. 
Again without rinsing, slides were immersed in 1% Safranin O for 5 minutes. After that 
slides were dehydrated through 3 changes of Absolute Alcohol for 1 min. Cleared slides 
through 3 changes of Xylene.Coverslips were used with a permanent mounting media.  
 
Real-time -PCR 
Temporomandibular joint chondrocytes that were grown in cell culture room were 
washed with 2 mL of Dulbecco’s phosphate-buffered saline, and trypsinized with 2 mL 
0.25% Trypsin with EDTA  and placed into the humidified incubator for 5 minutes. Five 
mL of the respective medium was added to the trypsinized plate, pipetted up and down and 
into to ensure mixture and plated in to six-well plates (100 k cells per well). Next day, 
serum-free media was used, and next morning, cells were treated with rhLOXL2, TGF-β1 
and a combination of rhLOXL2 and TGF-β1 with different concentrations. The plates were 
left for overnight. After that, cells were harvested using a scraper and 200 ul sample buffer. 
2 ul of nuclease-free water was loaded to the lower pedestal to measure the blank after that 
2 ul of the samples were loaded and measured. Using the spectrophotometer nanodrop ND-
1000 V3.5.1 
 
Reverse transcriptase Reaction 
To synthesize single-stranded cDNA from total RNA using High Capacity cDNA 
Reverse Transcription Kits (Cat. No. #4368814; Applied biosystem). 2✕ Reverse 
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Transcription Master Mix was prepared using all the reagents supplied in the kit. 10 µL of 
2✕RT master mix was transferred into PCR tubes (Cat. No. #12240225; thermoGrid) that 
contained 10 µL of RNA sample in each well, pipetted up and down two times to mix. 
Tubes were sealed and briefly centrifuged to spin down the contents and to eliminate any 
air bubbles before loading into My Cycler by Bio-Rad. The thermal cycler was 
programmed to conditions using PCR cycle as follows 25º C for 10 minutes, 37º C for 120 
minutes, 85º C for 5 minutes, and 4 º C HOLD. The reaction volume was set to 20 µL. 
 
Quantitative real-time PCR 
Quantitative real-time PCR (RT-qPCR) analysis was performed using TaqMan 
gene expression assays (Cat. No. 15596-026; Life Technologies), TaqMan®2x Universal 
PCR Master Mix (ref. # 4304437; Applied biosystem). TaqMan® Gene Expression Assay 
IDs for human and mouse probes were:  SOX9 (Hs01001343_g1 and Mm00448840_m1), 
MMP13 (Hs00233992_m1 and Mm00439491_m1), ACAN (Hs00153936_m1 and 
Mm00545794_m1), COL2A1 (Hs00264051_m1 and Mm01309565_m1), and LOXL2 
(Hs00158757_m1). Using 96 well plate 11 µl of Master Mix/gene was Pipetted and placed 
into each well. cDNA was dilute using RNase –free water (1:50 dilution). 9 µl of diluted 
cDNA was added to each of the wells and 9 ul of RNase-free water in the negative control 
wells. The plate was covered and centrifuged at 700 rpm for 2-3 min. Following 
centrifugation, the plate was loaded into 7300 real-time PCR system, SDS V1.3.1, with 20 
ul setting and was programmed to conditions using PCR cycle as follows 50º C for 2 
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minutes, 95º C for 10 minutes, 95º C for 15 second, and 60 º C minutes. The Cover Temp 
was set at 104.6 º C and Sample Temp was 25 º C. 
 
Isolation of high-quality total RNA 
Total RNA was extracted from paraffin-embedded sections of the femur, tibia, and 
TMJ condyle using Trizol reagent (Cat. No. 15596-026; Life Technologies) and FFPE 
RNA isolation kit (Cat. No. 73504; Qiagen). Tissue samples were Homogenized in 1 ml of 
TRIZOL reagent per 50 to 100 mg of tissue using a grinder. Cells grown in 6 well plate 
were rinsed with ice-cold PBS once. Cells were lyzed by adding 300ul/well of TRIZOL 
Reagent and scraping it with cell scraper. The cell lysate were Passed several times through 
a pipette and vortexed thoroughly. Homogenized samples were incubated for 5 minutes at 
room temperature then Centrifuged and the supernatant was transferred to new tubes. 0.2 
ml of chloroform per 1 ml of TRIZOL Reagent was added. Samples were Vortex 
vigorously for 15 seconds and incubated at room temperature for 5 minutes. The samples 
were centrifuged at 12,000 x g for 15 minutes at 2 to 8
0
C. Following centrifugation, the 
mixture separates into lower red, phenol-chloroform phase, interphase, and a colorless 
upper aqueous phase. RNA remains exclusively in the aqueous phase. The upper aqueous 
phase was transferred into fresh tubes.0.6 ml of isopropyl alcohol per 1 ml of TRIZOL 
Reagent was added for the initial homogenization. Samples were incubated at 15 to 30
o
C 
for 10 minutes and centrifuged at 12,000 x g for 10 minutes at 2 to 4
o
C. The supernatant 
was removed and the RNA pellet was wash with 1 ml of 75% ethanol. The samples were 
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Mixed by vortexing and centrifuged at 7,500 x g for 5 minutes at 2 to 8 
o
C. The above 
washing procedure was repeated once and all leftover ethanol were removed. Following 
removal of ethanol, the RNA pellet were left to dry for 5-10 minutes. The RNA was 
dissolved in 100ul of DEPC-treated water by passing solution a few times through a pipette 
tip. Next 250ul of buffer RLT, 3.5ul of β-mercaptoethanol and 350ul of 70% ethanol were 
added and mixed with the dissolved RNA. After mixing, the samples were transferred into 
an RNeasy spin column placed in 2ml collection tube and were centrifuged for 30 seconds 
at 10,000 rpm. 700ul of RW1 buffer were added and were centrifuged for 30 seconds at 
10,000 rpm. Next, 500ul of RPE buffer were added and centrifuged for 2 minutes at 10,000 
rpm twice. The RNeasy spin column were placed in 1.5ml collection tube and 50ul of 
RNase-free water were added and left for 4 minutes and then centrifuged for 1 minutes at 
10,000 rpm to elute the RNA. 
 
 
Isolation of proteins 
Proteins are isolated from the phenol-ethanol supernatant layer left over after the 
DNA precipitation step. DNA was isolated from the interphase and phenol-chloroform 
layer saved from the Phase separation step. 0.3 mL of 100% ethanol was added and mixed. 
At room temperature, the samples were incubated for 2–3 minutes and then centrifuged at 
2,000 × g for 5 minutes at 4°C to pellet the DNA. The phenol-ethanol supernatants were 
removed and saved into new tubes for protein isolation, and the DNA pellets were stored 
in -200C for future use. 3 mL of isopropanol was added to the phenol-ethanol supernatant 
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tubes and were left for 10 minutes at room temperature and then centrifuged at 12,000 × g 
for 10 minutes at 4°C to pellet the protein and discarded the supernatant. The protein pellets 
were washed with 1.5 mL of washing solution (0.3 M guanidine hydrochloride in 95% 
ethanol) and were incubated for 20 minutes at room temperature and then centrifuged at 
7500 × g for 5 minutes at 4°C. These steps were repeated twice, and the wash solution were 
discarded every time. 2 mL of 100% ethanol was added to the protein pellets and then 
incubated for 20 minutes at room temperature and centrifuged at 7500 × g for 5 minutes at 
4°C. The ethanol wash was discarded and the protein pellet were left for 5–10 minutes to 
air dry.  200 ul of sample buffer (made in the lab) was added to the protein pellet and pipet 
up and down until the protein is resuspended. Next, the proteins were centrifuged at 10,000 
× g for 10 minutes at 4°C to sediment any insoluble material. 
 
 
In vivo implantation of human articular and TMJ chondrocytes in nude mice 
As an alternative to various models based on human chondrocytes (Schuller GC, 
2008), (Endres M, 2007) & (Yahara Y, 2016) we established a model using implants of 
primary TMJ-OA or HAC-OA chondrocytes embedded in Matrigel. For in vivo 
applications, freshly isolated TMJ-OA cells or frozen cells obtained from Cell Application 
Inc., were expanded only once to maintain their phenotype prior to preparation of implants. 
Freshly prepared 106 TMJ-OA or HAC-OA chondrocytes in 50 µL medium, from TMJ or 
knee joints of three different patients with OA, were mixed with Matrigel at a 1:1 ratio. 
The total 100 µL of Matrigel: chondrocyte suspension were implanted subcutaneously in 
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the backs of nude mice (three implants/mouse) and allowed to grow for a week. These 
implants were treated locally with weekly injections of 30-µL suspensions of Ad-RFP-
LOXL2 or Ad-RFP-EV (n = 5/condition), for 6 weeks. Transduction was confirmed by 
visualization of RFP by in vitro imaging systems (IVIS) each week. One implant from each 
mouse was then processed for RNA isolation, and the other two were prepared for 
histologic analysis and stained with Safranin O/Fast Green (American Mastertek Inc.). 
 
Data analysis  
Data analyses were performed using two-way analysis of variance (ANOVA) with 
Bonferroni post-hoc analysis or Student’s t test (Graph Pad Prism 5 software). All 
experiments were performed three times each using cells derived from a different HAC-N, 
HAC-OA, or TMJ patient sample. Each data point is represented in the graphs as mean ± 
SEM of three experiments with significance set at P < 0.05. 
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RESULTS 
 
Loxl2 does not induce Cell proliferation  
In order to evaluate if LOXL2 can induce the proliferation of OA chondrocytes, we 
treated the cells with different doses of rhLOXL2 and Adv-LOXL2. HAC-OA from the 
temperomandibular joint were treated with different concentrations of rhLOXL2 (ng/ul). 
Measured using CyQUANT Cell Proliferation Assays and showed no increase in the 
number of cells compared with control. Also, there was a significant decrease in the 
number of cells that were treated with rhLOXL2 (15, 30 & 500 ng/ul) concentrations, as 
can be seen in (Fig. 1). HAC-OA from knee cells were treated in the same manner with 
different concentrations of rhLOXL2 (ng/ul), as can be seen in (Fig. 2). Loxl2 did not 
induce proliferation, and there was a significant decrease in all concentrations measured 
using a t-test. HAC-OA from knees were also treated with different MOI concentrations of 
Adv-RFP-LOXL2 and showed no proliferation and a significant decrease in 2.5 MOI 
contestation, as can be seen in (Fig. 3).  
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Figure 1: Proliferation of TMJ-OA cells with different concentrations of 
recombinant human LOXL2 (rhLOXL2) and using CyQUANT Cell Proliferation Assay. 
The statistically significant difference is indicated (*; 0.05 by Student’s t test).  
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Figure 2: The proliferation of HAC-OA from Knee cells treated with different 
concentrations of Recombinant Human Lysyl Oxidase Homolog 2/LOXL2 (rhLOXL2) a 
using CyQUANT Cell Proliferation Assays/Fluorescence. (*). The statistically significant 
difference is indicated (*; 0.05 by Student’s t test). 
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Figure 3: Proliferation of HAC-OA from Knee cells treated with different concentrations 
of Adv-RFP-LOXL2 compared to vehicle treatment showed a significant decrease in 2.5 
MOI contestation (*) The statistically significant difference is indicated (*; 0.05 by 
Student’s t test). using CyQUANT Cell Proliferation Assays/Fluorescence. 
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Regulation of LOXL2 mRNA by OA-related factors  
In order to evaluate if  LOXL2 expression is modulated by anabolic and catabolic 
factors involved in OA, we treated Human articular OA chondrocytes (HAC-OA with 
TNF-α, IL-1β, or transforming growth factor-β1 (TGF-β1) at 10 or 30 ng/mL for 24 h. 
LOXL2 mRNA levels were assessed by RT-qPCR. Data are represented as mean ± SEM 
of three independent experiments with 95% confidence interval (CI) (*P < 0.001; Student’s 
t test). LOXL2 mRNA levels in HAC-OA were induced significantly by TGF-β1 (twofold) 
stimulation, whereas they were downregulated 0.5-fold and 0.7-fold, respectively, by TNF-
α and IL-1β (Fig. 4). These results indicate that LOXL2 gene expression can be modulated 
by key factors affecting OA related processes in cartilage.  
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Figure 4: Regulation of LOXL2 gene expression by osteoarthritis (OA)-related mediators. 
LOXL2 gene expression was significantly upregulated by TGF-β1 (P < 0.001) and 
downregulated by TNF-α (P < 0.001) and IL-1β (P < 0.001). 
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LOXL2 inhibits signaling pathways induced by IL-1β and TGF-β1 
In order to evaluate if LOXL2 attenuates IL-1β and TGF-β1 induced downstream 
signaling pathways in OA, HAC-OA were treated with IL-1β and TGF-β1 and their effect 
evaluated by analyzing the expression of phosphorylated NF-κB and ERK. Transduction 
of HAC-OA with Ad-RFP-LOXL2 inhibited IL-1β-induced phospho-NF-κB/p65 and 
TGF-β1-induced phospho- ERK1/2 levels compared to cells transduced with Ad- RFP-EV, 
as shown by western blotting (Fig. 5a and b). 
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Figure 5: (a) LOXL2 inhibits IL-1β-induced phospho-NF-ĸB and TGF-β1-induced 
phospho-ERK1/2 shown by western blot analysis, whereas TNF-α induced phospho-NF-
ĸB and phospho-ERK1/2 are not affected. (b) Quantification is shown as fold-change 
normalized to β-actin (*P < 0.001; Student’s t test; n = 3).  
a 
b 
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LOXL2 promotes anabolic responses in implants of the human knee and TMJ-OA 
chondrocytes in vivo  
To evaluate if LOXL2 can maintain the human cartilage phenotype long-term (6 
weeks) and induce specific chondrogenic differentiation in vivo, we produced a model of 
OA using chondrocyte/Matrigel constructs implanted subcutaneously in the backs of nude 
mice. We used adenoviral delivery of LOXL2 in implants to evaluate the expression of 
critical genes such as SOX9, ACAN, and COL2A1, which are involved in chondrogenesis. 
This model is an effective alternative to the human-cell-based models used previously 
(Schuller GC, 2008), (Endres M, 2007) & (Yahara Y, 2016): it replicates the 3-dimensional 
cartilage environment in vivo, uses specific growth factors that preserve the differentiated 
phenotype for cartilage regeneration (Vinatier C, 2009), and prevents the tissues from 
becoming fibrotic after 6–9 weeks (Peretti GM, 2000) and myogenic (Cairns DM, 2012). 
Weekly injections of Ad-RFP-EV or Ad-RFP-LOXL2 near the chondrocyte-Matrigel 
implants were performed for up to 6 weeks. IVIS imaging confirmed successful 
transduction by Ad-RFP-EV or Ad-RFPLOXL2 (Fig. 6a). After 6 weeks, histological 
sections of the retrieved implants stained with Safranin O/Fast Green and Alcian blue 
showed that LOXL2 transduction increased proteoglycan deposition and cartilage 
formation. However, implants after transduction with Ad-RFP-EV did not show Safranin 
O or Alcian blue staining, consistent with loss of chondrogenic phenotype and 
proteoglycan deposition (Fig. 6b). Molecular analysis of implants by RT-qPCR showed 
that LOXL2 treatment increased the levels of LOXL2, SOX9, COL2A1, and ACAN 
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mRNA compared to control, whereas MMP13 and ADAMTS5 mRNA levels were not 
affected significantly in HAC-OA implants (Fig. 6c) and TMJ-OA implants (Fig.6d).  
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Figure 6: LOXL2 promotes anabolic responses in implants of the human knee and 
osteoarthritic temporomandibular joint (TMJ-OA) chondrocytes in vivo. a) In vitro 
imaging systems (IVIS) imaging of human articular chondrocytes (HAC)/Matrigel 
implants in nude mice after local injection every week for 6 weeks with adenoviruses for 
transient expression of LOXL2 (Ad-RFP-LOXL2) or Ad-RFP-empty vector (EV) (Ad-
RFP empty). Knee HAC-OA/ Matrigel implants were injected weekly with Ad-RFP-
LOXL2 or Ad-RFP-EV, harvested after 6 weeks, and analyzed by Safranin O/Fast Green 
and Alcian blue (b) with relative quantification (c-d), and RT-qPCR using human primers 
(e-f), (n = 5/condition; *P < 0.05 and **P < 0.01; Student’s t test). SOX9 sex determining 
region Y-box containing gene 9, ACAN aggrecan, COL2A1 collagen type II α1, MMP 
matrix 
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DISCUSSION  
 
LOXL2 does not induce the proliferation of human TMJ or knee OA chondrocytes 
in contrast to studies performed in fibrosis and cancer (Wu & Zuh, 2015). However, we 
showed that LOXL2 induces differentiation and attenuates OA related catabolic signaling 
pathways. There was a significant decrease in proliferation of TMJ-OA and knee-OA cells 
with specific concentrations of rh LOXL2. , Thus, exogenous expression of LOXL2 does 
not affect chondrocyte proliferation, but promotes chondrogenic lineage-specific gene 
expression, increases COL2A1 expression. These findings were published recently 
(Alshenibr A, 2017). Pro-inflammatory cytokines such as TNF-α and IL-1β act as catabolic 
factors, promoting synovitis and altering chondrocyte differentiation, function, and 
viability (Chevalier X, 2010) & (Liu-Bryan R, 2015). We showed that LOXL2 attenuated 
the signaling pathways induced by TGF-β1, TNF-α, and IL-1β. In chondrocytes, IL-1β and 
TNF-α activate the canonical NF-κB pathway, leading to catabolic and inflammatory 
responses (Marcu KB, 2010) & (Olivotto E, 2015), whereas non-canonical NF-kB 
signaling promotes chondrocyte hypertrophy (Olivotto E, 2013) & (Rigoglou S, 2013). 
Recent studies showed that TGF-β1 expression in subchondral bone induces OA (Zhen G, 
2013), and TGF-β1 inhibitors are chondroprotective in knee-OA and TMJ-OA in animal 
models (Zhen G, 2013), (Long E, 2016) & (Blaney Davidson EN, 2007). We found that 
LOXL2 inhibits IL-1β- induced phosphorylation of the NF-κB/p65 subunit, which permits 
translocation of the p65/p50 complex to the nucleus, and TGF-β1-induced ERK1/2 
phosphorylation, which is required for many anabolic responses in cartilage. LOX can 
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directly interact with TGF- β1 and inhibit TGF-β1 activity (Atsawasuwan P, 2008). Thus, 
LOXL2 could interact with TGF-β1 to negatively regulate its activity, or influence TNF-α 
and IL-1β-induced signaling pathways. LOXL2 could also induce amine oxidation at TGF-
β1 receptor, inhibiting its activity, or attenuate downstream inflammatory signaling 
pathways NF-kB and ERK1/2. Indeed, LOXL2 overexpression reduces the expression of 
the TGF-β-responsive gene PAI1 and negatively regulates TGF-β1 responsive gene sets 
and SMAD 2/3 phosphorylation. We conclude that LOXL2 could inhibit TGF-β1 
signaling, though, alternatively, LOXL2 could be a downstream target of TGF-β1 and act 
through feedback inhibition of TGF β1-induced signaling. 
LOXL2 is a naturally occurring enzyme and could have potential application in 
anabolic therapies. The ECM regulates diverse cellular functions, including proliferation, 
migration, and differentiation, and ECM remodeling is crucial for the development of 
normal organs. In contrast, dysregulation of the ECM increases LOXL2 expression and 
contributes to several pathological conditions such as fibrosis and invasive cancer 
(Atsawasuwan P, 2008), (Barker HE, 2012) & (Akiri G, 2003) LOXL2 is increased in 
cancer and fibrosis as a consequence of aberrant signaling pathways and inflammatory 
mediators leading to remodeling of ECM (Torres S, 2015). Although LOXL2 is present in 
the damaged regions, the concentration of LOXL2 may be overcome by catabolic 
mediators such as IL-1β and TNF-α present in degenerative cartilage, which prevent 
anabolic effects induced by LOXL2 during late stages of OA. These possibilities are under 
investigation in mouse models to evaluate LOXL2 as a potential therapeutic agent by the 
early vs. delayed administration, frequency, and dose of application. Current approaches 
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in the development of disease-modifying OA drugs are to: (1) inhibit the ECM-degrading 
enzymes to prevent erosion of cartilage, (2) inhibit catabolic pro-inflammatory cytokines 
to protect chondrocytes against stress and inflammatory insults, and (3) develop anabolic 
agents to promote chondrocyte proliferation and selective differentiation (Johnson K, 
2014). Unlike other agents that affect one or two targets, our preliminary studies show that 
LOXL2 could have direct and indirect effects on all of these processes in OA as a potential 
pro-anabolic and anti-catabolic factor.  
Long-term in vivo implanted human chondrocytes lose their chondrogenic 
phenotype and differentiation potential or become fibrous in the absence of specific 
stimulating anabolic factors or scaffolds (Vinatier C, 2009). Earlier studies are showing 
that LOXL2 knockdown in chondrocytes in vitro inhibits expression of these genes and 
proteoglycan deposition (Iftikhar M,2010). We investigated both TMJ and knee joints 
affected by OA. The TMJ differs in structure compared to other joints (Hinton RJ, 2014), 
with a secondary cartilage distinct from the articular cartilage of limbs and cartilage in the 
cranial base. However, despite structural and functional differences in the cartilage 
between the knee joint and TMJ, our findings show that LOXL2 could have roles in the 
pathophysiology of OA in both types of joint.  
Our hypothesis that LOXL2 acts as a specific anabolic factor in chondrocytes is 
supported by data showing that: (1) LOXL2 gene expression is regulated by OA-related 
mediators (2) LOXL2 overexpression increases SOX9, COL2A1, and ACAN mRNA 
levels, which are related to the differentiated chondrocyte phenotype, without increasing 
MMP13 or ADAMTS5; (3) LOXL2 promotes a differentiated phenotype, unlike the dual 
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global effects were seen in TGF-β1 (Zhen G, 2013)and (4) LOXL2 promotes a 
differentiated phenotype and maintains the chondrogenic lineage in vivo. Taken together, 
LOXL2 promotes anabolic responses, chondrocyte differentiation, and ECM production. 
We are evaluating the role of LOXL2 in mouse OA models, which will provide a basic 
nderstanding of LOXL2 function for future clinical application.  
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